文献速递中药与中成药合理使用

三叶片口服吸收的改良生物药剂学分类系统模型建立

Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
PubMed 文献 · J Ethnopharmacol · 2019-08-07

该研究以三叶片为对象,通过体外试验与体内绝对生物利用度比较经典BCS与改良BCS对中药复方吸收程度的预测能力。结果显示除荷叶碱外五种代表性成分多属III/IV类,改良BCS与体内吸收相关性优于经典方法,提示三叶片口服制剂为BCS III/IV类药物。

要点

  • 三叶片五种代表性成分中除荷叶碱外均属BCS III/IV类,吸收较差。
  • 荷叶碱绝对生物利用度达61.91%,为五种成分中最佳。
  • 改良BCS分类结果与体内吸收的相关性优于经典BCS。

核心结论

  • 三叶片五种代表性成分(除荷叶碱外)均为BCS III/IV类,与绝对生物利用度结果相关良好,属难吸收物质。
  • 改良BCS分类结果与体内吸收的相关性优于经典方法,更适用于三叶片表征。
  • 三叶片口服制剂为BCS III/IV类药物。

研究设计与样本

  • 选取三叶片代表性成分进行多项体外试验,并与BCS结果比较以评价准确性与适用性。
  • 将溶出度与稳定性等基于产品特性的参数纳入,建立改良BCS并与经典方法比较。
  • 基于代表性成分的绝对生物利用度,考察各分类系统预测中药复方吸收程度的能力。

主要发现

  • 经典BCS中,五种代表性成分(除荷叶碱外)均为III类;荷叶碱经Caco-2细胞试验为I/II类,经外翻肠囊试验为III/IV类。
  • 改良BCS中,芍药苷为III类,芦丁、金丝桃苷和丹酚酸B为III/IV类;荷叶碱经Caco-2细胞试验为I/II类,经外翻肠囊试验为III/IV类。
  • 荷叶碱为五种成分中最佳,基于体内生物利用度试验的绝对生物利用度达61.91%。

关键数值与推荐

  • 经典BCS:除荷叶碱外五种代表性成分均为III类;荷叶碱Caco-2法为I/II类,外翻肠囊法为III/IV类。
  • 改良BCS:芍药苷为III类;芦丁、金丝桃苷、丹酚酸B为III/IV类;荷叶碱Caco-2法为I/II类,外翻肠囊法为III/IV类。
  • 荷叶碱绝对生物利用度为61.91%。

临床怎么用

  • 可参考改良BCS模型预测三叶片等中药复方口服制剂的体内吸收程度。
  • 对BCS III/IV类成分需关注其低吸收特性对生物利用度的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: As one of the new drugs of traditional Chinese medicine, Sanye Tablet is employed as a hypolipidemic in the traditional medicine, but the biopharmaceutical properties of the drug is still unclear. AIM OF THE STUDY: Through the study of biopharmaceutical properties, the classical biopharmaceutics classification system (BCS) can be used to classify and predict the in vivo absorption properties. On this basis, the biopharmaceutical properties closely related to traditional Chinese medicine preparations are added and a modified BCS model is established to predict and judge the absorption degree of traditional Chinese medicine compound. MATERIALS AND METHODS: Representative components of Sanye Tablet were selected and subjected to different in vitro tests. The experimental results were compared with the results of the BCS to evaluate the accuracy and applicability to Sanye Tablet. We take parameters of dissolution and stability based on product characteristics into account. A "modified-BCS" was developed and the results of the improved method and the classic method were compared. Also the ability of each classification system to predict and determine the extent of absorption of the Chinese herbal compound was investigated based on the absolute bioavailability of representative components. RESULTS: For classic BCS, the five representative components (except for nuciferine) are all class III, nuciferine is class I/II obtained by Caco-2 cell assay and class III/IV obtained by everted gut sac assay. For modified BCS, paeoniflorin is class III, rutin, hyperoside and salvianolic acid B are class III/IV, and nuciferine is class I/II based on Caco-2 cell assay, class III/IV based on everted gut sac assay. Nuciferine is the best of the five components, with absolute bioavailability reaching 61.91% based on in vivo bioavailability test. CONCLUSIONS: The five representative components (except for nuciferine) are all class III/IV, which correlates well with the absolute bioavailability results and demonstrates that they are poorly absorbed substances. The correlation between the classification results obtained using the "modified-BCS" and absorption in the body is better than the correlation obtained using the classic method, suggesting that the improved BCS is more suitable for the characterization of Sanye Tablet. These results indicate that the oral formulation of Sanye Tablet is a BCS III/IV drug.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li H, Cao X, Liu Y, et al. Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet). J Ethnopharmacol. 2019. PMID: 31400507. doi:10.1016/j.jep.2019.112148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。